Acambis will be responsible for the advancement of its Phase II candidate as well as filing for approval.

Sanofi pasteur inked a deal related to development and marketing of Acambis’ ChimeriVax™-West Nile vaccine. Acambis stands to earn over $80 million in this exclusive global collaboration.

ChimeriVax-West Nile is in a Phase II safety, tolerability, and immunogenicity trial in the U.S. in adults over 41 years. Acambis will continue development and will also be responsible for the filing of a license application in the U.S.

Sanofi pasteur will initially pay $10 million. Acambis will be eligible for development funding as well as $70 million in pre- and post-marketing milestone fees based on product approval and sales in the U.S. If the vaccine receives registration in other countries, the company will receive additional post-marketing milestone payments. Acambis will also get royalties on global net sales.

“This vaccine candidate is the most promising in the industry and would help meet a growing public health need,” commented Wayne Pisano, president and CEO of sanofi pasteur.

Previous articleBeike Biotech and Tsinghua Univ. to Help Establish China’s Position in Stem Cell Engineering and Reprogramming Research
Next articleXenomics Patents Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics